We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+20.25%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$537M
AUM Growth
+$121M
Cap. Flow
+$76M
Cap. Flow %
14.17%
Top 10 Hldgs %
39.95%
Holding
98
New
28
Increased
18
Reduced
12
Closed
34

Top Buys

1
NBIX icon
Neurocrine Biosciences
NBIX
+$12.9M
2
XLRN
Acceleron Pharma
XLRN
+$9.49M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$9.34M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$9.04M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$8.82M

Top Sells

1
ABT icon
Abbott
ABT
+$15.4M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$14.1M
3
CELG
Celgene Corp
CELG
+$12.7M
4
SHPG
Shire pic
SHPG
+$12.2M
5
AERI
Aerie Pharmaceuticals
AERI
+$7.8M

Sector Composition

1 Healthcare 59.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRTC icon
76
iRhythm Holdings
IRTC
$3.64B
– –
-115,182
Closed -$3.46M
PBYI icon
77
CALL
Puma Biotechnology
PBYI
$434M
– –
-200,000
Closed -$6.14M
PRGO icon
78
Perrigo
PRGO
$1.48B
– –
-70,000
Closed -$5.83M
RCKT icon
79
CALL
Rocket Pharmaceuticals
RCKT
$376M
– –
-75,000
Closed -$1.83M
SRPT icon
80
CALL
Sarepta Therapeutics
SRPT
$1.82B
– –
-200,000
Closed -$5.49M
VCYT icon
81
Veracyte
VCYT
$4.72B
– –
-200,000
Closed -$1.55M
VNDA icon
82
Vanda Pharmaceuticals
VNDA
$327M
– –
-46,000
Closed -$734K
VTVT icon
83
vTv Therapeutics
VTVT
$130M
– –
-5,000
Closed -$966K
NVRO
84
DELISTED
NEVRO CORP.
NVRO
– –
-90,000
Closed -$6.54M
ICPT
85
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-70,000
Closed -$7.61M
ISEE
86
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-86,100
Closed -$416K
AERI
87
DELISTED
Aerie Pharmaceuticals
AERI
– –
-175,000
Closed -$7.8M
ENDP
88
DELISTED
Endo International plc
ENDP
– –
-250,000
Closed -$4.12M
ALXN
89
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-115,000
Closed -$14.1M
MNK
90
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-135,000
Closed -$6.73M
MDCO
91
DELISTED
Medicines Co
MDCO
– –
-75,000
Closed -$2.55M
HZNP
92
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-129,100
Closed -$2.09M
SGYP
93
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-55,000
Closed -$335K
TSRO
94
DELISTED
TESARO, Inc.
TSRO
– –
-17,000
Closed -$2.77M
ARIA
95
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-75,000
Closed -$933K
CELG
96
DELISTED
Celgene Corp
CELG
– –
-110,000
Closed -$12.7M
NDRM
97
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-330,000
Closed -$7.33M
QGENF
98
DELISTED
QIAGEN NV
QGENF
– –
-135,000
Closed -$3.78M
1 2 3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Ghost Tree Capital held 98 positions worth $537M, up 29% from $415M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Ghost Tree Capital deployed $76M of net new capital in Q1 2017, opening 28 new positions and adding to 18 existing holdings. Its largest new stake was Neurocrine Biosciences: 300,000 shares worth $13M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 73% a quarter earlier.

On the sell side, the largest reduction was Shire pic, an estimated $12.2M trimmed.

  • Ghost Tree Capital's largest Q1 2017 buy was Neurocrine Biosciences: 300,000 shares worth $13M.
  • Ghost Tree Capital added most to Acceleron Pharma in Q1 2017, an estimated $9.49M increase.
  • Ghost Tree Capital's biggest Q1 2017 reduction was Shire pic, cutting an estimated $12.2M.
  • Ghost Tree Capital fully exited Abbott in Q1 2017, selling an estimated $15.4M.
  • Ghost Tree Capital's ten largest holdings make up 40% of its $537M portfolio in Q1 2017.
  • Ghost Tree Capital opened 28 new positions and closed 34 in Q1 2017.
  • Ghost Tree Capital's portfolio value rose 29% quarter-over-quarter to $537M.

Based on Ghost Tree Capital's 13F filing for Q1 2017, filed 15 May 2017.